New experimental weight loss drug shows greater effectiveness than Ozempic

Based on early trial results reported on March 7, it appears the experimental pill may cause greater weight loss than existing injectable treatments such as Ozempic, Wigoby, and Munjaro.

The drug, called amicretin, reduced people’s weight by 13 percent in three months. This is more than double his amount observed at Ozempic and Wegoby specifically. “From the limited data we have, this approach seems a little more exciting,” he says. Daniel Drucker At the University of Toronto, Canada.

The results come from a three-month, placebo-controlled trial, so it’s too early to know how amicretin compares to other drugs in terms of long-term efficacy and safety. said Drucker, who was not involved in the trial but was consulted, as well as manufacturer Novo Nordisk and other drug companies.

The diabetes drug Ozempic and the weight loss drug Wegoby are two brand names for the compound semaglutide. They work by mimicking a gut hormone called GLP-1 that is normally released after meals. This makes a person feel full, reduces appetite, and stimulates the release of the blood sugar-regulating hormone insulin.

Semaglutide leads to a loss of about 15 percent of body weight when taken for a year, but after that the weight plateaus and the injections need to be continued for a long time or it tends to gradually come back.

Another weight loss injectable called Mounjaro, also known as Tirzepatide or Zepbound, was launched last year. It mimics GLP-1 and an additional intestinal hormone called GIP. Using Mounjaro, you seem to lose about 21 percent of your weight over the first year and five months of her life before your weight loss plateaus.

However, amicletin mimics GLP-1 and another hormone called amylin, and appears to be even more potent, at least during the first three months of treatment. Reuters reports that people who took amicletin lost 13 percent of their weight during this period, Nordisk announced today. Those who took the placebo pill had a 1% decrease. This is higher than Wegovy and Ozempic’s 6 percent and Munjaro’s equivalent figure of around 7.5 percent.

But we can only know for sure how the drugs will fare over the long term if they are compared under exactly the same circumstances in a single study, Drucker said. “This is not a head-to-head trial.”

Another caveat is that while drugs that act by mimicking GLP-1 have been used to treat type 2 diabetes for more than a decade and their safety profile is well understood, amylin mimetics That’s not the case.

Novo Nordisk also said: Amicretin’s side effects were similar to those of Wegoby, and tended to include nausea, vomiting, and diarrhea, especially when the dose was increased rapidly.

The availability in pill form could be a big advantage for people who don’t like injections, he says. Daniel Chancellor Global Pharmaceutical Business Analyst cytherine. “Oral medications are very attractive.”

In addition to these three drugs, other weight loss drugs that mimic other gut hormones are also in development.